Pharmaceutical Firm Seeks Federal Clearance for Research Importation
February 26, 2025
February 26, 2025
WASHINGTON, Feb. 26 (TNSFR) -- Catalent Pharma Solutions, LLC has applied for federal authorization to import a Schedule I controlled substance for clinical research and analytical purposes. The company, based in Philadelphia, Pennsylvania, intends to bring in ibogaine, a psychoactive compound, in finished dosage form.
According to the Drug Enforcement Administration (DEA), the importation will be strictly for scientific activities, with no authorization for commercial distribution . . .
According to the Drug Enforcement Administration (DEA), the importation will be strictly for scientific activities, with no authorization for commercial distribution . . .